ALUMIS INC.

Listed Company

ALMSCIK 0001847367NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$24.05M

Net Income

$-243.30M

Total Assets

$411.94M

Equity

$301.30M

Shares Out

—

Op. Cash Flow

$-369.50M

ALMS$28.65+711.61% · past yearDBEQ Basic

Daily closing prices

Business

Alumis Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, with a focus on TYK2 inhibitors and monoclonal antibodies. The company's lead candidate, envudeucitinib (envu), is a second-generation TYK2 inhibitor in Phase 3 development for plaque psoriasis and Phase 2b for systemic lupus erythematosus. Alumis also develops A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory diseases, and lonigutamab, an IGF-1R monoclonal antibody for thyroid eye disease, acquired through the ACELYRIN merger. The company operates across multiple geographic markets including the United States, European Union, and Asia-Pacific regions.

Summary from 10-K filed 2026-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Total revenue	24	—	—
Research and development expenses, including related party expenses of $1,144 and $912 for the years ended December 31, 2025 and 2024, respectively	386	266	138
General and administrative expenses	92	35	20
Total operating expenses	478	301	158
Loss from operations	−454	−301	−158
Gain on bargain purchase	188	—	—
Interest income	14	12	3
Change in fair value of derivative liability	—	−5	−119,000
Other income (expenses), net	−169,000	−93,000	−68,000
Total other income (expense), net	202	7	3
Net loss before income taxes	−252	−294	—
Income tax benefit	9	0	—
Net loss	−243	−294	−155
Unrealized gain (loss) on marketable securities, net	148,000	38,000	129,000
Total comprehensive loss	−243	−294	−155
Net loss per share attributable to common stockholders, basic	−2.86	−10.38	−72.08
Net loss per share attributable to common stockholders, diluted	−2.86	−10.38	−72.08
Weighted-average shares of common stock outstanding, basic	85	28	2
Weighted-average shares of common stock outstanding, diluted	85	28	2

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	90	170	46	—
Restricted cash	82,000	—	113,000	—
Marketable securities	219	119	3	—
Research and development prepaid expenses	3	13	3	—
Other prepaid expenses and current assets	7	5	2	—
Total current assets	318	306	53	—
Restricted cash, non-current	1	1	1	—
Property and equipment, net	18	21	22	—
Intangible assets	51	—	—	—
Operating lease right-of-use assets, net	17	13	13	—
Other assets, non-current	6	7,000	7,000	—
Total assets	412	341	90	—
Accounts payable	10	10	1	—
Research and development accrued expenses	35	29	11	—
Deferred revenue, current	1	—	—	—
Other accrued expenses and current liabilities	22	11	7	—
Operating lease liabilities, current	5	2	2	—
Total current liabilities	73	51	21	—
Operating lease liabilities, non-current	32	29	31	—
Deferred revenue, non-current	3	—	—	—
Deferred tax liability	2	—	—	—
Share repurchase liability	123,000	813,000	2	—
Other liabilities, non-current	207,000	—	—	—
Total liabilities	111	81	54	—
Commitments and contingencies (Note 9)	—	—	—	—
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—	—	—
Additional paid-in capital	1,203	919	25	—
Accumulated other comprehensive income (loss)	188,000	40,000	2,000	—
Accumulated deficit	−902	−659	−364	—
Total stockholders' equity	301	260	−339	−195
Total liabilities and stockholders' equity	412	341	90	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Net loss	−243	−294	−155
Stock-based compensation	44	19	9
Net accretion of discounts on marketable securities	−5	−4	−544,000
Depreciation and amortization	3	3	1
Non-cash lease expense	2	60,000	2
Loss on disposal of fixed assets	—	5,000	266,000
Impairment of long-lived assets	529,000	—	—
Research and development prepaid expenses	11	−11	6
Other prepaid expenses and other assets	17	−3	—
Other assets, non-current	−6	—	—
Accounts payable	−6	9	−642,000
Deferred revenue	4	—	—
Research and development accrued expenses	2	18	5
Other accrued expenses and current liabilities	6	4	2
Operating lease liabilities	−3	−2	−144,000
Other liabilities, non-current	207,000	—	—
Deferred income tax liability	−9	—	—
Net cash used in operating activities	−370	−255	−130
Maturities of marketable securities	448	128	76
Purchases of marketable securities	−209	−240	−11
Purchases of property and equipment	−653,000	−2	−4
Cash, cash equivalents and restricted cash acquired in connection with the ACELYRIN Merger	50	—	—
Net cash provided by (used in) investing activities	288	−114	60
Proceeds from issuance of redeemable convertible preferred stock and derivative liability, net of issuance costs	—	258	90
Proceeds from initial public offering, net of underwriter discounts and commissions and other offering costs	—	193	—
Proceeds from a private placement transaction	—	40	—
Proceeds from issuance of common stock upon exercise of stock options	489,000	596,000	453,000
Repurchase of common stock shares issued upon early exercised restricted common stock	−17,000	−6,000	−64,000
Proceeds from issuance of common stock under the 2024 ESPP	2	—	—
Net cash provided by financing activities	2	492	90
Net (decrease) increase in cash, cash equivalents and restricted cash	−80	123	20
Conversion of 168,489,871 shares of redeemable convertible preferred stock upon the closing of initial public offering	—	639	—
Equity consideration transferred in connection with the ACELYRIN Merger	238	—	—
Vesting of early exercised stock options and unvested restricted shares of common stock	673,000	1	2
Right-of-use assets obtained in exchange for operating lease liabilities	2	—	14
Recognition of derivative liability upon issuance of redeemable convertible preferred stock	—	9	2
Settlement of derivative liability upon issuance of redeemable convertible preferred stock	—	−14	−2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ALUMIS INC.'s CIK number?

ALUMIS INC.'s SEC CIK number is 0001847367 (1847367). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ALUMIS INC.'s SEC filings?

All of ALUMIS INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ALUMIS INC. last report earnings?

ALUMIS INC. (ALMS) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001847367-26-000009). This is ALUMIS INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is ALUMIS INC.'s most recent earnings 8-K?

ALUMIS INC.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001847367-26-000009. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ALUMIS INC.'s latest earnings 8-K →
Look up any company's CIK number →